

Anna LÃ³pez-Ferrer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9617557/publications.pdf>

Version: 2024-02-01

29
papers

559
citations

687220

13
h-index

642610

23
g-index

33
all docs

33
docs citations

33
times ranked

820
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. <i>Dermatologic Therapy</i> , 2022, 35, e15231.	0.8	17
2	A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. <i>International Journal of Clinical Pharmacy</i> , 2022, 44, 725-730.	1.0	6
3	Artritis psoriásica. <i>Medicina Clínica</i> , 2022, 159, 40-46.	0.3	9
4	Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2878-2880.	1.1	4
5	Definition of minimal disease activity in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 422-430.	1.3	11
6	Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. <i>British Journal of Dermatology</i> , 2021, 185, 660-662.	1.4	17
7	Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 222-226.	1.1	8
8	Adaptación lingüística y cultural al español del cuestionario Psoriatic arthritis UnclutteRed screening Evaluation (PURE-4). <i>Actas Dermo-sifiligráficas</i> , 2020, 111, 655-664.	0.2	4
9	Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2821-2829.	1.3	24
10	AB0770...DESCRIBING A COHORT OF PATIENTS WITH PSORIATIC ARTHRITIS ACCORDING TO THE BODY MASS INDEX: EXPERIENCE IN A JOINT RHEUMATOLOGY-DERMATOLOGY CLINIC. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1683.1-1683.	0.5	0
11	Biosimilars for the treatment of psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 993-1000.	1.4	30
12	Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 553-559.	1.3	51
13	Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. <i>Journal of Dermatological Treatment</i> , 2019, 30, 424-429.	1.1	57
14	Subclinical enthesopathy of extensor digitorum tendon is highly prevalent and associated with clinical and ultrasound alterations of the adjacent fingernails in patients with psoriatic disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1728-1736.	1.3	21
15	Unidades psoriasis-artritis: 3 años después. <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 101-103.	0.2	1
16	Sesgo en el Cuestionario de productividad laboral y deterioro de las actividades: psoriasis (WPAI:PSO) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.2	0
17	Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. <i>Journal of Dermatological Treatment</i> , 2018, 29, 334-346.	1.1	39
18	Triple paradoxical reaction due to adalimumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e71-e73.	1.3	3

#	ARTICLE	IF	CITATIONS
19	The safety of ustekinumab for the treatment of psoriatic arthritis. Expert Opinion on Drug Safety, 2017, 16, 733-742.	1.0	23
20	Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service. Journal of Dermatological Treatment, 2017, 28, 623-630.	1.1	16
21	Crusted (Norwegian) scabies: an under-recognized infestation characterized by an atypical presentation and delayed diagnosis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 483-485.	1.3	13
22	ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice. Journal of the American Academy of Dermatology, 2016, 74, 1066-1072.	0.6	65
23	Modelo de eficiencia de los frmacos biolgicos en el tratamiento de la psoriasis moderada-grave durante un ao en las condiciones de uso en Espaa. Actas Dermo-sifiligrficas, 2016, 107, 34-43.	0.2	7
24	Etanercept en el tratamiento de la artritis psorisica. Actas Dermo-sifiligrficas, 2015, 106, 252-259.	0.2	4
25	Secukinumab (AIN457) for the treatment of psoriasis. Expert Review of Clinical Immunology, 2015, 11, 1177-1188.	1.3	20
26	Anlisis de coste-eficacia incremental de los tratamientos biolgicos para la psoriasis en los momentos de valoracin significativos para la prctica clnica. Actas Dermo-sifiligrficas, 2014, 105, 951-953.	0.2	7
27	Vismodegib: revisin. Actas Dermo-sifiligrficas, 2014, 105, 744-751.	0.2	13
28	Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. British Journal of Dermatology, 2013, 169, 1141-1147.	1.4	46
29	Artritis psorisica: lo que el dermatlogo debe saber (Parte 1). Actas Dermo-sifiligrficas, 2010, 101, 578-584.	0.2	6